These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36876127)

  • 1. Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity.
    Welling MS; Mohseni M; van der Valk ES; van Hagen JM; Burgerhart JS; van Haelst MM; van Rossum EFC
    iScience; 2023 Mar; 26(3):106199. PubMed ID: 36876127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide Treatment in a Morbidly Obese Adolescent with a
    Çamtosun E; Akıncı A; Kayaş L; Çiftçi N; Tekedereli İ
    J Clin Res Pediatr Endocrinol; 2023 May; 15(2):225-229. PubMed ID: 34584129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation.
    Elkhenini HF; New JP; Syed AA
    Clin Obes; 2014 Apr; 4(2):121-4. PubMed ID: 25826735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanocortin 4 receptor (MC4R) gene variants in children and adolescents having familial early-onset obesity: genetic and clinical characteristics.
    Aykut A; Özen S; Gökşen D; Ata A; Onay H; Atik T; Darcan Ş; Özkinay F
    Eur J Pediatr; 2020 Sep; 179(9):1445-1452. PubMed ID: 32185475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients.
    Cooiman MI; Alsters SIM; Duquesnoy M; Hazebroek EJ; Meijers-Heijboer HJ; Chahal H; Le Beyec-Le Bihan J; Clément K; Soula H; Blakemore AI; Poitou C; van Haelst MM
    Obes Surg; 2022 Mar; 32(3):837-844. PubMed ID: 34984630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.
    Fojas EGF; Radha SK; Ali T; Nadler EP; Lessan N
    Front Endocrinol (Lausanne); 2021; 12():792354. PubMed ID: 35095762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes.
    Poitou C; Puder L; Dubern B; Krabusch P; Genser L; Wiegand S; Verkindt H; Köhn A; von Schwartzenberg RJ; Flück C; Pattou F; Laville M; Kühnen P; Clément K
    Surg Obes Relat Dis; 2021 Aug; 17(8):1449-1456. PubMed ID: 34083135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Billes SK; Sinnayah P; Cowley MA
    Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
    Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
    Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Bupropion Plus Naltrexone for the Management of Obesity.
    Booth K; Clements JN
    J Pharm Technol; 2016 Jun; 32(3):125-132. PubMed ID: 34860947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.